print version 

Find company
Home About the ProjectContact usFor the Clients
Enter code or ISIN
 
alpha / industry search

Issuers' Corner
Press Releases
Annual Reports Library

Financial Statements
SEC & FFMS Filings
Corporate Presentations
GM Materials
Issues Documents
Corporate Governance Materials
Russian Company Guide
Company Profiles
Corporate Calendar
Markets Corner
Consensus Estimates
Media Corner
News Line


Get updates



Home  Issuers' Corner  Press Releases REGISTER LOG IN

Press Releases

company search
all press releases
all Pharmstandard press releases

Pharmstandard

April 23, 2007

JSC Pharmstandard announces US$11.55 to US$14.55 per GDR and US$46.20 to US$58.20 per share price range

23 April 2007, Moscow: JSC Pharmstandard (“Pharmstandard” or the “Company”), a leading domestic pharmaceutical company in Russia, today announces the price range for the initial offering by Augment Investments Limited (the “Selling Shareholder”) of ordinary shares in the Company (the “Shares”) and global depository receipts (“GDRs”) with four GDRs representing one Share (the “Offering”).

Summary of the Offering

- The indicative price range is between US$11.55 and US$14.55 per GDR and US$46.20 and US$58.20 per Share.

- This price range reflects an implied market capitalisation of Pharmstandard of between approximately US$1.75 billion and US$2.20 billion.

- The Selling Shareholder has granted the Joint Global Coordinators an over-allotment option to purchase GDRs representing up to 15% of the total number of GDRs to be sold in the Offering.

- The Company intends to seek a listing of the GDRs on the official list of the UK Listing Authority and an admission to trading on the regulated market of the London Stock Exchange PLC and of its Shares on the Moscow Interbank Currency Exchange. The Shares are listed on the Russian Trading System (RTS).

- The bookbuilding process and international roadshow begin today.

- The Company has appointed Citi and UBS Investment Bank as Joint Global Coordinators of the Offering.

Commenting on today’s announcement, Igor Krylov, CEO of Pharmstandard said:

“We look forward to meeting investors on the forthcoming roadshow. Our recent results have confirmed our position as Russia’s leading domestic pharmaceutical company and we are confident that we have the right growth strategy in place to enable us to benefit from the rapidly developing Russian pharmaceutical sector.”

 

 

 

Search by industry

Agriculture, Foresty and Fishing | Chemicals | Engineering | Ferrous Metals | Financial, Insurance & Real Estate | Food & Kindred Products | General Construction | Information Technology | Media & Publishing | Non-Ferrous Metals | Oil & Gas | Pharmaceuticals | Power Industry | Precious Metals and Diamonds | Telecommunications | Transportation | Wholesale & Retail Trade

Search by alpha index

A B C D F G H I K L M N O P R S T U V W X Z


Site Map
© RUSTOCKS.com
Privacy Statement | Disclaimer